Guggenheim lowered the firm’s price target on Ardent Health (ARDT) to $13 from $15 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health Announces Leadership Change in Hospital Services
- Ardent Health Earnings Call: Strength Today, Caution Ahead
- Ardent Health price target lowered to $15 from $16 at Leerink
- Ardent Health price target lowered to $13 from $14 at UBS
- Ardent Health Partners: Cost Efficiencies Balance Utilization Headwinds, Justifying a Hold Rating